Amplitude Ventures
Amplitude Ventures is a venture capital firm based in Montreal, with additional offices in Toronto and Vancouver, that specializes in early-stage investments. The firm focuses on biotechnology and healthcare, particularly targeting emerging Canadian companies. Since its founding in 2012, Amplitude Ventures has raised over $700 million in equity capital across private and public markets. In November 2019, it launched its first private capital fund, a $200 million initiative aimed at investing in leading Canadian precision medicine companies. The firm’s 2023 vintage fund, Amplitude Ventures Fund II, extends its investment reach to the United States and Europe, seeking opportunities in sectors such as diagnostic equipment, therapeutic devices, drug delivery, surgical devices, monitoring equipment, biotechnology, and drug discovery.
Congruence Therapeutics operates as a biotechnology company working at the interface of computational and experimental drug discovery to design novel small molecules for diseases of protein misfolding.
InVivo AI is a Montreal-based company founded in 2017 that specializes in using artificial intelligence to enhance pharmaceutical research and development. The company primarily focuses on preclinical toxicology, aiming to improve the efficiency and effectiveness of drug development processes. By leveraging advanced AI technologies, InVivo AI seeks to transform traditional methodologies in the pharmaceutical industry, ultimately contributing to faster and more reliable outcomes in drug safety assessments.
Thryv Therapeutics is a biopharmaceutical company focused on developing therapies for long QT syndrome, a genetic disorder characterized by prolonged ventricular repolarization, which can lead to life-threatening arrhythmias. The company's research centers on SGK-1, a regulator of sodium channels in heart cells, which is implicated in the overactivity associated with long QT syndrome. By targeting this kinase, Thryv aims to address the underlying causes of the disorder and improve treatment options for affected patients. Based in Laval, Canada, the company is committed to advancing its pipeline to enhance patient outcomes in this critical area of cardiovascular health.
Giiant is a preclinical-stage biotech company that, with its proprietary Precision Delivery technology platform, designs gut-restricted, tissue-specific, small molecule, drug therapeutics with various biological targets in gastroenterology. Its lead program GT-2108 is a microbiota-activated PDE4 inhibitor prodrugs, with improved drug tolerability and enhanced therapeutic effect.
Milestone Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes etripamil for the treatment of cardiovascular indications. It is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada, as well as for the treatment of atrial fibrillation, angina, and other cardiovascular indications. The company was founded in 2003 and is headquartered in Montréal, Canada.
Imagia’s mission is to detect and quantify cancer changes early.
When it matters.
Despite systematic imaging and new genetic testing, tumor changes are often detected too late to improve cancer patient outcomes.
Our Artificial Clinical Intelligence Platform enables us to provide critical information and timely imaging insights for primary tumors and metastasis for each cancer patient thus personalizing their cancer care continuum.
Deep Radiomics™ — uniting radiomics and deep learning — utilizes existing routine clinical imaging data to discover robust imaging biomarkers that predict cancer patient outcomes.